Apellis Pharmaceuticals Inc is a pioneering biopharmaceutical firm dedicated to developing innovative treatments for autoimmune and inflammatory diseases by targeting the complement system. Its flagship product, EMPAVELI, is designed for various conditions including paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. Apellis is also advancing SYFOVRE for age-related macular degeneration and has other promising therapies in early-stage trials. Founded in 2009 and headquartered in Waltham, Massachusetts, the company collaborates with industry leaders to enhance its drug development pipeline.
Pre-Market Stock Futures: Risk-on appeared back, at least for the last two days, as the stock market put together another rally on Wednesday, with hopes for an end to the war in…
Pre-Market Stock Futures: Futures are trading higher after an explosive rally on Tuesday, sparked by the President’s comments that he wants to end the war soon. While this is hardly the final…
Pre-Market Stock Futures: Futures are trading higher as we get ready to conclude another dreadful week on Wall Street. The song remains the same as soaring oil prices, another week of war…
When Apellis Pharmaceuticals (APLS) secured FDA approval for EMPAVELI in C3 glomerulopathy and IC-MPGN last summer, the stock was trading near $28. Today it sits at $19.96, down 31% over the past…
William Temple U.S. stocks pared early gains on Wednesday, with the Dow slipping despite robust bank earnings from Bank of America and Morgan Stanley, fueled by trading windfalls. The S&P 500 edged up 0.21%…
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
Friday's top analyst upgrades and downgrades included Allstate, Cisco Systems, CSX, FIGS, Meta Platforms, Nike, ON Semiconductor, Pinterest, SentinelOne and Zscaler.
Wednesday afternoon's top analyst upgrades and downgrades included AeroVironment, AutoZone, BigCommerce, NXP Semiconductors, Roblox, Stitch Fix and more.
Friday’s top analyst upgrades and downgrades included American Tower, Best Buy, Beyond Meat, Editas Medicine, Freeport McMoRan, First Solar and UnitedHealth.
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Thursday, including Apple, AutoDesk, Beazer Homes and New Fortress Energy.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including Amicus Therapeutics, Bloomin' Brands, Children’s Place and Seagate Technology.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including Amazon, Bloom Energy, Chipotle and Disney.
Wednesday's top analyst upgrades, downgrades and initiations included Accenture, Anheuser-Busch InBev, Cerner, CNOOC, Delta Air Lines, Ford, GoDaddy, Kinder Morgan, Newmont, NuStar, United Airlines and Visa.
